Maximilian R.
- Country
- Germany
- Department
- Medizinische Klinik 2 - Hämatologie / Onkologie
Research Overview
- A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications
- Phase III Trial of BI 764532 Plus Atezolizumab, Carboplatin, and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Phase II Evaluation of Atezolizumab with Platinum and Etoposide in Advanced Large-Cell Neuroendocrine Carcinoma of the Lung in Non-Curative Patients
Data & Insights
Has run more than one trial at 132 of 345 partner sites.
Specializations
Gynecologic Oncology
The investigator specializes in treating advanced ovarian cancer, with particular focus on innovative therapeutic approaches for both newly diagnosed and recurrent cases. Their expertise extends to managing peritoneal cancer and fallopian tube cancer, particularly in advanced stages.
- Folate receptor alpha targeting therapies
- Platinum-based combination treatments
- PARP inhibitor applications
Their work encompasses comprehensive treatment strategies for high-grade epithelial ovarian cancer, including surgical interventions and targeted therapeutic approaches.
Thoracic Oncology
The investigator focuses on developing treatment strategies for non-small cell lung cancer and rare thoracic malignancies. Their expertise includes managing large-cell neuroendocrine cancer of the lung, particularly in advanced or metastatic settings.
- Immunotherapy combinations
- Targeted antibody-drug conjugates
- Advanced stage lung cancer treatments
Their research integrates platinum-based therapies with novel immunotherapeutic approaches for thoracic malignancies.
Innovative Therapeutics
The investigator explores cutting-edge therapeutic combinations, including immunotherapy agents and novel targeted treatments. Their work involves evaluating new treatment paradigms for various advanced cancers.
- Combination therapy strategies
- Novel drug development
- Biomarker-driven treatments
Their research focuses on integrating targeted therapies with conventional treatment approaches to improve patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.